Loading...

Puma Biotechnology

Nasdaq:PBYI
Snowflake Description

Adequate balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PBYI
Nasdaq
$450M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. The last earnings update was 66 days ago. More info.


Add to Portfolio Compare Print
  • Puma Biotechnology has significant price volatility in the past 3 months.
PBYI Share Price and Events
7 Day Returns
-2%
NasdaqGS:PBYI
-2.6%
US Biotechs
0.6%
US Market
1 Year Returns
-77.8%
NasdaqGS:PBYI
-12.3%
US Biotechs
4.7%
US Market
PBYI Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Puma Biotechnology (PBYI) -2% -9% -65.6% -77.8% -64.7% -80.2%
US Biotechs -2.6% 1.9% -4.4% -12.3% 8.5% 8.9%
US Market 0.6% 4.2% 2.7% 4.7% 38% 43.5%
1 Year Return vs Industry and Market
  • PBYI underperformed the Biotechs industry which returned -12.3% over the past year.
  • PBYI underperformed the Market in United States of America which returned 4.7% over the past year.
Price Volatility
PBYI
Industry
5yr Volatility vs Market

PBYI Value

 Is Puma Biotechnology undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Puma Biotechnology to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Puma Biotechnology.

NasdaqGS:PBYI Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 11.7%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:PBYI
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.33
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.327 (1 + (1- 21%) (39.92%))
1.499
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.5
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.499 * 5.96%)
11.66%

Discounted Cash Flow Calculation for NasdaqGS:PBYI using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Puma Biotechnology is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:PBYI DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 11.66%)
2020 -15.00 Analyst x1 -13.43
2021 47.00 Analyst x1 37.69
2022 103.00 Analyst x2 73.98
2023 166.50 Analyst x2 107.09
2024 222.82 Est @ 33.83% 128.34
2025 277.41 Est @ 24.5% 143.10
2026 327.26 Est @ 17.97% 151.17
2027 371.10 Est @ 13.4% 153.52
2028 408.94 Est @ 10.2% 151.50
2029 441.48 Est @ 7.96% 146.47
Present value of next 10 years cash flows $1,079.42
NasdaqGS:PBYI DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $441.48 × (1 + 2.73%) ÷ (11.66% – 2.73%)
$5,075.91
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $5,075.91 ÷ (1 + 11.66%)10
$1,684.02
NasdaqGS:PBYI Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,079.42 + $1,684.02
$2,763.44
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,763.44 / 38.61
$71.57
NasdaqGS:PBYI Discount to Share Price
Calculation Result
Value per share (USD) From above. $71.57
Current discount Discount to share price of $11.66
= -1 x ($11.66 - $71.57) / $71.57
83.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Puma Biotechnology is available for.
Intrinsic value
>50%
Share price is $11.66 vs Future cash flow value of $71.57
Current Discount Checks
For Puma Biotechnology to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Puma Biotechnology's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Puma Biotechnology's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Puma Biotechnology's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Puma Biotechnology's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:PBYI PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-2.60
NasdaqGS:PBYI Share Price ** NasdaqGS (2019-07-12) in USD $11.66
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,084 Publicly-Listed Companies 18.01x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Puma Biotechnology.

NasdaqGS:PBYI PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:PBYI Share Price ÷ EPS (both in USD)

= 11.66 ÷ -2.60

-4.48x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Puma Biotechnology is loss making, we can't compare its value to the US Biotechs industry average.
  • Puma Biotechnology is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Puma Biotechnology's expected growth come at a high price?
Raw Data
NasdaqGS:PBYI PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.48x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
61.7%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 0.81x
United States of America Market PEG Ratio Median Figure of 2,125 Publicly-Listed Companies 1.59x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Puma Biotechnology, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Puma Biotechnology's assets?
Raw Data
NasdaqGS:PBYI PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $1.13
NasdaqGS:PBYI Share Price * NasdaqGS (2019-07-12) in USD $11.66
United States of America Biotechs Industry PB Ratio Median Figure of 436 Publicly-Listed Biotechs Companies 2.98x
United States of America Market PB Ratio Median Figure of 5,239 Publicly-Listed Companies 1.81x
NasdaqGS:PBYI PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:PBYI Share Price ÷ Book Value per Share (both in USD)

= 11.66 ÷ 1.13

10.35x

* Primary Listing of Puma Biotechnology.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Puma Biotechnology is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Puma Biotechnology's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Puma Biotechnology has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

PBYI Future Performance

 How is Puma Biotechnology expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
61.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Puma Biotechnology expected to grow at an attractive rate?
  • Puma Biotechnology's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Puma Biotechnology's earnings growth is expected to exceed the United States of America market average.
  • Puma Biotechnology's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:PBYI Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:PBYI Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 61.7%
NasdaqGS:PBYI Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 12.7%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 23.2%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.1%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:PBYI Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:PBYI Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 461 128 77 5
2022-12-31 406 99 26 5
2021-12-31 345 60 -32 6
2020-12-31 289 22 -84 7
2019-12-31 287 16 -95 7
NasdaqGS:PBYI Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 284 -34 -99
2018-12-31 251 -24 -114
2018-09-30 202 -67 -147
2018-06-30 145 -114 -210
2018-03-31 94 -143 -243
2017-12-31 28 -172 -292
2017-09-30 6 -178 -301
2017-06-30 -158 -289
2017-03-31 -143 -278
2016-12-31 -142 -276
2016-09-30 -134 -265
2016-06-30 -136 -260

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Puma Biotechnology's earnings are expected to grow significantly at over 20% yearly.
  • Puma Biotechnology's revenue is expected to grow by 12.7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:PBYI Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Puma Biotechnology Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:PBYI Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.68 2.89 0.69 4.00
2022-12-31 0.58 1.31 -0.02 4.00
2021-12-31 -0.78 0.17 -1.88 6.00
2020-12-31 -2.06 -1.00 -3.50 9.00
2019-12-31 -2.54 -0.63 -3.93 9.00
NasdaqGS:PBYI Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -2.60
2018-12-31 -2.99
2018-09-30 -3.89
2018-06-30 -5.59
2018-03-31 -6.52
2017-12-31 -7.85
2017-09-30 -8.19
2017-06-30 -8.14
2017-03-31 -8.08
2016-12-31 -8.29
2016-09-30 -8.16
2016-06-30 -8.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Puma Biotechnology will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Puma Biotechnology's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Puma Biotechnology has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

PBYI Past Performance

  How has Puma Biotechnology performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Puma Biotechnology's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Puma Biotechnology does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Puma Biotechnology's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Puma Biotechnology's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Puma Biotechnology's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Puma Biotechnology Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:PBYI Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 283.54 -99.32 155.09 153.66
2018-12-31 250.99 -113.58 146.19 164.85
2018-09-30 201.52 -146.96 136.11 176.78
2018-06-30 144.97 -209.94 140.10 189.93
2018-03-31 94.20 -243.44 124.89 199.93
2017-12-31 27.69 -291.96 106.69 207.81
2017-09-30 6.08 -300.54 92.29 213.95
2017-06-30 -289.14 73.82 216.43
2017-03-31 -277.90 61.16 217.39
2016-12-31 -276.01 53.80 222.80
2016-09-30 -265.07 46.92 218.84
2016-06-30 -259.71 41.71 218.79
2016-03-31 -257.80 34.98 223.95
2015-12-31 -239.28 31.81 208.47
2015-09-30 -225.05 30.27 195.56
2015-06-30 -200.48 25.33 175.73
2015-03-31 -174.63 23.70 151.35
2014-12-31 -141.97 19.36 122.92
2014-09-30 -110.43 14.28 96.39
2014-06-30 -88.87 12.68 76.37
2014-03-31 -62.67 11.04 51.81
2013-12-31 -54.66 9.79 45.05
2013-09-30 -60.63 20.47 40.32
2013-06-30 -72.20 26.30 46.03
2013-03-31 -74.31 25.80 48.60
2012-12-31 -74.35 24.81 49.64
2012-09-30 -62.29 20.11 42.18

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Puma Biotechnology has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Puma Biotechnology has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Puma Biotechnology improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Puma Biotechnology's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Puma Biotechnology has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

PBYI Health

 How is Puma Biotechnology's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Puma Biotechnology's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Puma Biotechnology is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Puma Biotechnology's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Puma Biotechnology's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Puma Biotechnology Company Filings, last reported 3 months ago.

NasdaqGS:PBYI Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 43.47 152.84 150.40
2018-12-31 34.31 151.89 165.42
2018-09-30 45.91 121.05 127.95
2018-06-30 38.30 120.27 134.51
2018-03-31 57.46 48.56 78.55
2017-12-31 53.30 48.48 81.70
2017-09-30 79.17 0.00 106.34
2017-06-30 120.11 0.00 151.65
2017-03-31 167.39 0.00 193.98
2016-12-31 209.82 0.00 229.48
2016-09-30 91.15 0.00 108.93
2016-06-30 127.08 0.00 143.79
2016-03-31 164.94 0.00 181.21
2015-12-31 206.01 0.00 215.89
2015-09-30 244.84 0.00 247.78
2015-06-30 274.78 0.00 282.37
2015-03-31 304.34 0.00 310.33
2014-12-31 117.05 0.00 141.33
2014-09-30 141.60 0.00 153.86
2014-06-30 167.04 0.00 178.35
2014-03-31 198.79 0.00 196.11
2013-12-31 83.99 0.00 83.95
2013-09-30 94.76 0.00 95.64
2013-06-30 107.03 0.00 107.52
2013-03-31 118.28 0.00 118.72
2012-12-31 128.91 0.00 137.41
2012-09-30 9.00 0.00 33.35
  • Puma Biotechnology's level of debt (351.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 351.6% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Puma Biotechnology has sufficient cash runway for more than 3 years based on current free cash flow.
  • Puma Biotechnology has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -17.6% each year.
X
Financial health checks
We assess Puma Biotechnology's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Puma Biotechnology has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

PBYI Dividends

 What is Puma Biotechnology's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Puma Biotechnology dividends. Estimated to be 0% next year.
If you bought $2,000 of Puma Biotechnology shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Puma Biotechnology's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Puma Biotechnology's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:PBYI Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2018 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:PBYI Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Puma Biotechnology has not reported any payouts.
  • Unable to verify if Puma Biotechnology's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Puma Biotechnology's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Puma Biotechnology has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Puma Biotechnology's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Puma Biotechnology's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Puma Biotechnology afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Puma Biotechnology has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

PBYI Management

 What is the CEO of Puma Biotechnology's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Alan Auerbach
COMPENSATION $6,152,550
AGE 49
TENURE AS CEO 7.8 years
CEO Bio

Mr. Alan H. Auerbach is the Founder of Puma Biotechnology, Inc. and has been its Executive Chairman, Chief Executive Officer and President since October 4, 2011 and serves as its Secretary. Mr. Auerbach is a Private Equity Partner at Burrill Private Equity. He serves as an Advisor at Los Angeles Syndicate of Technology, Inc. He founded Cougar Biotechnology, Inc. in May 2003 and served as its Chief Executive Officer and President since May 2003. From July 2009 to January 2010, he served as the Co-Chairman of the integration steering committee that provides leadership and oversight for the development and global commercialization of Cougar’s lead product candidate, abiraterone acetate. Prior to Cougar, from June 1998 to April 2003 Mr. Auerbach served as a Vice President and Senior Research Analyst at Wells Fargo Securities, LLC, Research Division, where he was responsible for research coverage of small and middle capitalization biotechnology companies, with a focus on companies in the field of oncology. He had primary responsibility for technical, scientific and clinical due diligence, as well as selection of biotechnology companies followed by Wells Fargo. During 2002, he ranked second in the NASDAQ/Starmine survey of analyst performance for stock picking in biotechnology. From August 1997 to May 1998, Mr. Auerbach was a Vice President, Research Analyst at the Seidler Companies, Inc., Research Division where he was responsible for research coverage of small capitalization biotechnology companies. Prior to his work as a biotechnology analyst, he worked for Diagnostic Products Corporation, where he designed and implemented clinical trials in the field of oncology. He has been an Executive Director of Puma Biotechnology, Inc., since 2011. He served as an Independent Director of Radius Health, Inc., from May 24, 2011 to December 29, 2017. He served as a Member of Cougar Biotechnology, Inc. from May 2003 to July 2009. Mr. Auerbach received an M.S. In Biomedical Enginerring from the University of Southern California and a B.S. in Biomedical Engineering from Boston University.

CEO Compensation
  • Alan's compensation has increased whilst company is loss making.
  • Alan's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Puma Biotechnology management team in years:

2.9
Average Tenure
52
Average Age
  • The tenure for the Puma Biotechnology management team is about average.
Management Team

Alan Auerbach

TITLE
Founder
COMPENSATION
$6M
AGE
49
TENURE
7.8 yrs

Maximo Nougues

TITLE
CFO & Principal Accounting Officer
COMPENSATION
$2M
AGE
50
TENURE
0.7 yrs

Richard Bryce

TITLE
Chief Medical & Scientific Officer
COMPENSATION
$2M
AGE
62
TENURE
1.9 yrs

Steven Lo

TITLE
Chief Commercial Officer
COMPENSATION
$2M
AGE
52
TENURE
3.8 yrs

Douglas Hunt

TITLE
Senior Vice President of Regulatory Affairs
COMPENSATION
$7M
AGE
54
TENURE
1.5 yrs

Mariann Ohanesian

TITLE
Senior Director of Investor Relations
TENURE
7.7 yrs

Charon Spencer

TITLE
Vice President of Human Resources
Board of Directors Tenure

Average tenure and age of the Puma Biotechnology board of directors in years:

3.9
Average Tenure
54
Average Age
  • The tenure for the Puma Biotechnology board of directors is about average.
Board of Directors

Alan Auerbach

TITLE
Founder
COMPENSATION
$6M
AGE
49
TENURE
7.8 yrs

Jay Moyes

TITLE
Lead Independent Director
COMPENSATION
$386K
AGE
65

Troy Wilson

TITLE
Independent Director
COMPENSATION
$356K
AGE
50
TENURE
5.8 yrs

Frank Zavrl

TITLE
Independent Director
COMPENSATION
$358K
AGE
53
TENURE
3.8 yrs

Adrian Senderowicz

TITLE
Independent Director
COMPENSATION
$353K
AGE
55
TENURE
3.9 yrs

Mike Miller

TITLE
Director
COMPENSATION
$1M
AGE
62
TENURE
1.4 yrs
Who owns this company?
Recent Insider Trading
  • Puma Biotechnology individual insiders have only sold shares in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
03. Jul 19 Sell Richard Bryce Individual 02. Jul 19 02. Jul 19 -89 $12.78 $-1,137
03. Jul 19 Sell Alan Auerbach Individual 02. Jul 19 02. Jul 19 -495 $12.78 $-6,326
06. Jun 19 Sell Richard Bryce Individual 03. Jun 19 03. Jun 19 -88 $15.07 $-1,326
05. Jun 19 Sell Alan Auerbach Individual 03. Jun 19 03. Jun 19 -483 $15.18 $-7,332
06. May 19 Sell Alan Auerbach Individual 02. May 19 02. May 19 -477 $32.38 $-15,445
06. May 19 Sell Richard Bryce Individual 02. May 19 02. May 19 -85 $32.38 $-2,752
03. Apr 19 Sell Richard Bryce Individual 02. Apr 19 02. Apr 19 -88 $35.78 $-3,149
03. Apr 19 Sell Alan Auerbach Individual 02. Apr 19 02. Apr 19 -491 $35.79 $-17,573
22. Mar 19 Sell Alan Auerbach Individual 04. Mar 19 04. Mar 19 -496 $38.62 $-19,156
22. Mar 19 Sell Richard Bryce Individual 04. Mar 19 04. Mar 19 -88 $38.66 $-3,402
06. Feb 19 Sell Richard Bryce Individual 04. Feb 19 04. Feb 19 -89 $27.77 $-2,472
06. Feb 19 Sell Charles Eyler Individual 04. Feb 19 04. Feb 19 -87 $27.64 $-2,405
06. Feb 19 Sell Alan Auerbach Individual 04. Feb 19 04. Feb 19 -345 $27.80 $-9,591
04. Jan 19 Sell Richard Bryce Individual 03. Jan 19 03. Jan 19 -1,210 $20.67 $-25,011
04. Jan 19 Sell Alan Auerbach Individual 03. Jan 19 03. Jan 19 -4,424 $20.67 $-91,444
04. Jan 19 Sell Charles Eyler Individual 03. Jan 19 03. Jan 19 -1,210 $20.67 $-25,011
X
Management checks
We assess Puma Biotechnology's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Puma Biotechnology has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

PBYI News

Simply Wall St News

How Puma Biotechnology, Inc. (NASDAQ:PBYI) Can Impact Your Portfolio Volatility

With a beta of 0.97, (which is quite close to 1) the share price of Puma Biotechnology has historically been about as voltile as the broader market. … That makes it somewhat unusual that it has a beta value so close to the overall market. … What this means for you: It is probable that there is a link between the share price of Puma Biotechnology and the broader market, since it has a beta value quite close to one.

Simply Wall St -

Investors Who Bought Puma Biotechnology (NASDAQ:PBYI) Shares Five Years Ago Are Now Down 78%

Check out our latest analysis for Puma Biotechnology Given that Puma Biotechnology didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … A Different Perspective While the broader market gained around 3.1% in the last year, Puma Biotechnology shareholders lost 73%. … If you would like to research Puma Biotechnology in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.

Simply Wall St -

Have Insiders Been Selling Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares?

So we'll take a look at whether insiders have been buying or selling shares in Puma Biotechnology, Inc. … As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.' Check out our latest analysis for Puma Biotechnology The Last 12 Months Of Insider Transactions At Puma Biotechnology Over the last year, we can see that the biggest insider sale was by the Founder, Alan Auerbach, for US$91k worth of shares, at about US$20.67 per share. … Insiders sold Puma Biotechnology shares recently, but they didn't buy any.

Simply Wall St -

Does Puma Biotechnology, Inc.'s (NASDAQ:PBYI) CEO Pay Compare Well With Peers?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Alan Auerbach's Compensation Compare With Similar Sized Companies. … has a market cap of US$1.3b, and is paying total annual CEO compensation of US$2.8m.

Simply Wall St -

Introducing Puma Biotechnology, The Stock That Tanked 78%

Puma Biotechnology isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … When a company doesn't yet make profits, we'd generally expect to see good revenue growth. … Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

Simply Wall St -

When Will Puma Biotechnology Inc (NASDAQ:PBYI) Turn A Profit?

Puma Biotechnology Inc's (NASDAQ:PBYI):. … Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. … The US$841m market-cap posted a loss in its most recent financial year of -US$292.0m and a latest trailing-twelve-month loss of -US$147.0m shrinking the gap between loss and breakeven.

Simply Wall St -

Does Puma Biotechnology Inc's (NASDAQ:PBYI) CEO Pay Compare Well With Peers?

Understanding how CEOs are incentivised to run and grow their company is an important aspect of investing in a stock. … Incentives can be in the form of compensation, which should always be structured in a way that promotes value-creation to shareholders. … CEOs leading companies of similar size and profitability

Simply Wall St -

Want To Invest In Puma Biotechnology Inc (NASDAQ:PBYI)? Here's How It Performed Lately

Today I will examine Puma Biotechnology Inc's (NASDAQ:PBYI) latest earnings update (31 March 2018) and compare these figures against its performance over the past couple of years, in addition to how the rest of PBYI's industry performed. … Were PBYI's earnings stronger than its past performances and the industry. … PBYI is loss-making, with the most recent trailing twelve-month earnings of -US$243.43m (from 31 March 2018), which compared to last year has become.

Simply Wall St -

Interested In Healthcare? Why Puma Biotechnology Inc (NASDAQ:PBYI) May Be The Entry Point

Check out our latest analysis for Puma Biotechnology What’s the catalyst for Puma Biotechnology's sector growth? … Puma Biotechnology lags the pack with its lower growth rate of 19.33% over the past year, which indicates the company will be growing at a slower pace than its biotech peers. … If Puma Biotechnology has been on your watchlist for a while, now may be the time to enter into the stock, if you like its growth prospects and are not highly concentrated in the biotech industry.

Simply Wall St -

One Thing To Consider Before Buying Puma Biotechnology Inc (NASDAQ:PBYI)

Generally, an investor should consider two types of risk that impact the market value of PBYI. … PBYI, with its market capitalisation of US$1.93B, is a small-cap stock, which generally have higher beta than similar companies of larger size. … I test PBYI’s ratio of fixed assets to total assets in order to determine how high the risk is associated with this type of constraint.

Simply Wall St -

PBYI Company Info

Description

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Details
Name: Puma Biotechnology, Inc.
PBYI
Exchange: NasdaqGS
Founded: 2010
$450,221,132
38,612,447
Website: http://www.pumabiotechnology.com
Address: Puma Biotechnology, Inc.
10880 Wilshire Boulevard,
Suite 2150,
Los Angeles,
California, 90024,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS PBYI Common Stock Nasdaq Global Select US USD 18. Apr 2012
DB 0PB Common Stock Deutsche Boerse AG DE EUR 18. Apr 2012
Number of employees
Current staff
Staff numbers
272
Puma Biotechnology employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/15 00:27
End of day share price update: 2019/07/12 00:00
Last estimates confirmation: 2019/07/09
Last earnings filing: 2019/05/10
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.